by Nirali N. Shah
In honor of Women’s History Month, ASTCT is proud to spotlight Dr. Nirali N. Shah, a leader in transplantation and cellular therapy.
by Blood Advances
Researchers suspect that ablation of the transcription factor Blimp-1 might address the lack of durable efficacy observed with chimeric antigen receptor T-cells (CAR-T) targeting B-cell maturation...
by Alex Kadhim
A recent study published in Journal for Immunotherapy of Cancer investigates the utility of DNA barcoded peptide-major histocompatibility complex (pMHC) multimers in detecting and monitoring minor...
by Blood
Study findings support the oral microbiome as a potential pathway for preventing or managing chronic graft-versus-host disease (cGVHD) following hematopoietic cell transplantation (HCT).
by ASTCT Advocacy Update
The ASTCT Committee on Payer Relations has updated its standardized Request for Information (RFI) forms for 2025.
by Rahul Banerjee, MD, FACP
One of the most predictable toxicities of autologous stem cell transplantation (ASCT) for multiple myeloma (MM) — even more so than mucositis — is hair loss.